Is lamivudine a safe and effective therapy for patients with chronic hepatitis B and advanced liver disease?
Karayiannis
Peter
P
Department of Medicine A, Imperial College, London, UK. p.karayiannis@imperial.ac.uk
Thomas
Howard C
HC
D001706:Biopsy; D018450:Disease Progression; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008099:Liver / Q000000981:diagnostic imaging / Q000473:pathology; D008103:Liver Cirrhosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome; D014463:Ultrasonography
D006514:Hepatitis B Surface Antigens; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine